Factors moderating the relative effectiveness of varenicline and nicotine replacement therapy in clients using smoking cessation services
Addiction2017Vol. 113(2), pp. 313–324
Citations Over Time
Neil J. Walker, Heather L. Gainforth, Vasiliki Kiparoglou, Hayley Robinson, Hugo van Woerden, Robert West
Abstract
Varenicline use was associated with higher smoking cessation rates than nicotine replacement therapy in routine clinical practice, irrespective of a wide range of smoker characteristics, but the difference was less in certain intervention settings, most notably pharmacy but also GP practice, compared with community setting.
Related Papers
- Smoking cessation therapy during pregnancy.(2012)
- → Pharmacotherapy guidelines for smoking cessation in primary healthcare clinics(2024)2 cited
- Smoking cessation therapy considerations for patients with chronic kidney disease.(2008)
- Clinical observation of varenicline for smoking cessation(2011)
- → Assessing GP use of varenicline therapy for smoking cessation(2014)